Core Viewpoint - The court ruled in favor of Ai Fen in a defamation case against Duan Moumin, ordering the latter to delete false statements made on social media, publicly apologize, and compensate for damages [1][2][3]. Group 1: Case Background - The case was initiated by Ai Fen, a chief physician at Wuhan Central Hospital, against Duan Moumin, who is the Deputy Secretary of the Party Committee and Director of Public Affairs at Aier Eye Hospital [1]. - Duan Moumin allegedly made multiple defamatory statements on his Weibo account, accusing Ai Fen of actions such as "forging photos to frame colleagues" and "accepting kickbacks" [1]. Group 2: Court Findings - The court confirmed the facts presented by Ai Fen and found that Duan Moumin's statements were malicious and damaging to Ai Fen's reputation [2]. - The court emphasized that individuals have the right to protect their reputation and that Duan Moumin's actions constituted a violation of Ai Fen's rights [2][3]. Group 3: Court Ruling - The court ordered Duan Moumin to delete the defamatory content within ten days and to cease any further defamatory statements about Ai Fen [3]. - Duan Moumin was also required to publicly apologize on his Weibo account for a minimum of 30 days, with the content subject to court review [3]. - The court awarded Ai Fen a total of 5,000 yuan for mental distress and related legal costs, while partially supporting her claim for additional economic damages [2][3].

问：如今随着医疗技术的飞速发展，近视手术方式日新月异，请介绍一下近视手术的一些技术原理 以及目前常用的一些手术方式类型。 问：安全性是患者较为关心的问题，在近视手术的过程中，爱尔眼科医院会采取哪些措施来全方位地 保障患者的手术安全？ 全流程的管理才能够保证手术的安全。首先是整个团队的配合，从术前开始就要为患者进行全方位 的术前检查，在国内要求激光类手术有11项的必备检查，在爱尔眼科医院会达到20多项，这么多数据汇 总是为了得到一个更完整的患者资料，进行更精准的个性化的设计。 其次是在手术中必须保证设备的安全运行、医护团队的高效配合、检眼师术前测量的精准性，保证 手术医生在手术当中稳定娴熟的技术和患者良好的沟通和配合。 目前近视手术分为"加法手术"和"减法手术"两大类主流的方式。"减法手术"就是激光类手术，又分 为半飞秒手术、全飞秒手术以及表层手术；"加法手术"是ICL植入术，也就是有晶体眼的人工晶状体的 植入手术。 "减法手术"里半飞秒手术也就是LASIK手术，它主要是在角膜基质上做一些切削，然后使角膜曲率 改变，从而获得一个清晰的术后视力；全飞秒手术是做一个非常微创的小切口，然后在角膜基质上做一 个透镜，再 ...

Core Points - The CSI All Share Healthcare Index increased by 0.05%, closing at 8642.42 points with a trading volume of 48.652 billion [1] - Over the past month, the index has risen by 0.21%, while it has decreased by 0.61% over the last three months and increased by 1.70% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI All Share Index, categorized into various levels of industries [1] Index Composition - The top ten weighted stocks in the CSI All Share Healthcare Index include: Heng Rui Medicine (6.67%), WuXi AppTec (5.32%), Mindray Medical (4.71%), Aier Eye Hospital (2.04%), Pian Zai Huang (2.0%), United Imaging Healthcare (1.66%), Yunnan Baiyao (1.6%), Kelun Pharmaceutical (1.27%), New Horizon (1.09%), and Shanghai Raist (1.03%) [1] - The market share of the index's holdings is distributed as follows: Shanghai Stock Exchange 50.92%, Shenzhen Stock Exchange 49.04%, and Beijing Stock Exchange 0.04% [2] - The index is composed entirely of the healthcare sector, with a 100% allocation to healthcare [2] Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to changes in the CSI All Share Index [2] - Special events affecting sample companies may lead to corresponding adjustments in the index, including delisting or corporate actions such as mergers and acquisitions [2]

湖南启元律师事务所 关于爱尔眼科医院集团股份有限公司 2025年第一次临时股东大会的 法律意见书 二零二五年三月二十六日 致：爱尔眼科医院集团股份有限公司 湖南启元律师事务所（以下简称"本所"）接受爱尔眼科医院集团股份有限 公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第一次临时 股东大会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、 出席会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证， 并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）等我国现行法律、法规、规范性文件以及《爱 尔眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）的有关规定 出具本法律意见书。 为出具本法律意见书，本所律师声明如下： （一）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律师的 文件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠， 无隐瞒、虚假或重大遗漏之处。 （二）本所律师遵循了勤勉尽责和诚实 ...

本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 爱尔眼科医院集团股份有限公司（以下简称"公司"）2025 年第一次临时 股东大会采用现场表决与网络投票相结合的方式召开。其中，通过深圳证券交易 所交易系统进行网络投票的时间为：2025 年 3 月 26 日 9:15 至 9:25、9:30 至 11:30， 13:00 至 15:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 3 月 26 日 9:15 至 15:00 期间的任意时间；现场会议于 2025 年 3 月 26 日 14:00 在长沙市芙蓉南路一段 188 号爱尔大厦 B1 层国际会议厅召开。本次股东大会由 公司董事会召集，董事长陈邦先生主持，公司董事、监事、高级管理人员、律师 等相关人士出席了本次会议。会议的召集、召开与表决程序符合法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 股东出席的总体情况： 证券代码：300015 股票简称：爱尔眼 ...

Group 1 - The core viewpoint of the article highlights that Aier Eye Hospital's stock closed down by 1.10%, with a rolling P/E ratio of 34.69 times and a total market capitalization of 125.915 billion yuan [1] - Aier Eye Hospital ranks 25th in the medical services industry, which has an average P/E ratio of 44.19 times and a median of 43.02 times [1] - As of September 30, 2024, Aier Eye Hospital had 372,778 shareholders, an increase of 19,315 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Aier Eye Hospital primarily engages in the diagnosis and treatment of various eye diseases, surgical services, and optical services [1] - The company has hosted significant academic conferences, including the 2019 International Retina Summit and the 2023 World Myopia Conference [1] - For the latest financial performance, Aier Eye Hospital reported a revenue of 16.302 billion yuan for the third quarter of 2024, a year-on-year increase of 1.58%, and a net profit of 3.452 billion yuan, up 8.50%, with a gross profit margin of 51.02% [1]

Group 1 - The ophthalmology industry is showing positive signals, with Aier Eye Hospital reporting an increase in both volume and price for refractive services [1][2] - In 2024, Aier Eye Hospital's operating indicators showed year-on-year growth, with revenue reaching 16.302 billion and net profit at 3.452 billion, surpassing the total net profit for 2023 [1] - The company is focusing on various areas such as medical services, international business expansion, talent development, digital transformation, and academic research [1] Group 2 - The macroeconomic environment is improving, benefiting the ophthalmology sector, with government policies aimed at boosting consumption and investment [2] - The demand for refractive surgery is increasing due to factors like youth myopia prevention and an aging population, with new technologies like All-Laser and ICL V5 being introduced [2][3] - Aier Eye Hospital has launched advanced surgical techniques and is leveraging AI in healthcare, enhancing service delivery and operational efficiency [3]

Group 1: Company Performance and Strategy - The company is experiencing stable operations and positive signals in the ophthalmology industry, with a focus on core business and high-quality development despite challenging external conditions [1] - The demand for ophthalmology services is expected to rise due to the implementation of national growth policies and economic recovery [1] - The company is committed to high-quality development, emphasizing innovation and reform to enhance core competitiveness [1] Group 2: Artificial Intelligence Applications - The company is actively integrating artificial intelligence (AI) to enhance medical capabilities, diagnostic efficiency, service quality, and management systems [2] - AierGPT, a specialized AI model for ophthalmology, has been deployed to improve service quality and digital transformation in eye care [2] - The digital human "Eyecho" is enhancing clinical service efficiency by integrating AI technologies across various service scenarios [2] Group 3: Refractive Surgery Business - The refractive surgery business is showing a positive trend with an increase in both volume and pricing, attributed to brand enhancement and upgraded surgical techniques [3] - New surgical techniques, such as All-Laser LASIK and ICL V5, are being introduced to meet diverse patient needs [3] - The penetration rate of refractive surgery in China remains low compared to developed countries, indicating significant growth potential [3] Group 4: International Expansion and Acquisitions - The company is pursuing a cautious and quality-focused approach to international acquisitions, ensuring thorough due diligence on potential targets [4] - Currently, overseas business accounts for 10%-15% of total revenue, with plans for further expansion [4] - The company has gained nearly a decade of international management experience, facilitating effective integration and collaboration across regions [4] Group 5: Future Outlook - The company anticipates challenges in 2024 due to a complex economic environment but remains focused on maintaining stable growth [4] - Key factors for future success include a mature medical service network, a patient-centered approach, and increasing demand for eye care services due to demographic trends [4] - The company aims to leverage its brand, technology, and talent to meet evolving patient needs and expand market presence [4]